双侧脑深部电刺激是晚期帕金森病更优选择:聚焦超声的成本效果阈值分析
该研究通过荟萃分析比较了脑深部电刺激(DBS)与射频消融(RF)治疗帕金森病的效用与成本效果,并建立聚焦超声(FUS)的成本效果成功阈值。基于此基准,FUS需在2年和5年内分别实现约16%和33%的UPDRS-3降幅才能成为最具成本效果的治疗。
要点
- 双侧DBS在22个月随访中效用最高,增加0.423质量调整生命年。
- FUS需2年内UPDRS-3降幅约16%、5年内约33%才具成本效果优势。
核心结论
- 双侧DBS为帕金森病提供最高效用和成本效果。
- 若达到既定成功阈值,FUS消融可能在社会成本角度优于双侧DBS的成本效果。
研究设计与样本
- 荟萃分析纳入1998-2018年关于DBS和RF靶向苍白球或丘脑底核治疗帕金森病的文章。
- 利用汇总的UPDRS-3运动评分和不良事件发生率计算效用,以Medicare报销费用作为社会成本代理。
主要发现
- 在22个月平均随访期内,双侧DBS增加的效用最高(0.423质量调整生命年),优于双侧RF、单侧DBS和单侧RF。
关键数值与推荐
- FUS需在2年期内实现UPDRS-3降低约16%才可能最具成本效果。
- FUS需在5年期内实现UPDRS-3降低约33%才可能最具成本效果。
临床怎么用
- 对于晚期帕金森病,双侧DBS应作为优先考虑的手术干预。
- 评估FUS时需参考其UPDRS-3降幅是否达到成本效果阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Parkinson disease (PD) impairs daily functioning for an increasing number of patients and has a growing national economic burden. Deep brain stimulation (DBS) may be the most broadly accepted procedural intervention for PD, but cost-effectiveness has not been established. Moreover, magnetic resonance image-guided focused ultrasound (FUS) is an emerging incisionless, ablative treatment that could potentially be safer and even more cost-effective. OBJECTIVE: To (1) quantify the utility (functional disability metric) imparted by DBS and radiofrequency ablation (RF), (2) compare cost-effectiveness of DBS and RF, and (3) establish a preliminary success threshold at which FUS would be cost-effective compared to these procedures. METHODS: We performed a meta-analysis of articles (1998-2018) of DBS and RF targeting the globus pallidus or subthalamic nucleus in PD patients and calculated utility using pooled Unified Parkinson Disease Rating Scale motor (UPDRS-3) scores and adverse events incidences. We calculated Medicare reimbursements for each treatment as a proxy for societal cost. RESULTS: Over a 22-mo mean follow-up period, bilateral DBS imparted the most utility (0.423 quality-adjusted life-years added) compared to (in order of best to worst) bilateral RF, unilateral DBS, and unilateral RF, and was the most cost-effective (expected cost: $32 095 ± $594) over a 22-mo mean follow-up. Based on this benchmark, FUS would need to impart UPDRS-3 reductions of ∼16% and ∼33% to be the most cost-effective treatment over 2- and 5-yr periods, respectively. CONCLUSION: Bilateral DBS imparts the most utility and cost-effectiveness for PD. If our established success threshold is met, FUS ablation could dominate bilateral DBS's cost-effectiveness from a societal cost perspective.
引用
- Mahajan UV, Ravikumar VK, Kumar KK, et al. Bilateral Deep Brain Stimulation is the Procedure to Beat for Advanced Parkinson Disease: A Meta-Analytic, Cost-Effective Threshold Analysis for Focused Ultrasound. Neurosurgery. 2021. PMID: 33295629. doi:10.1093/neuros/nyaa485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。